Copyright
©The Author(s) 2024.
World J Cardiol. Aug 26, 2024; 16(8): 469-483
Published online Aug 26, 2024. doi: 10.4330/wjc.v16.i8.469
Published online Aug 26, 2024. doi: 10.4330/wjc.v16.i8.469
Table 4 Intervention characteristics of randomized controlled trials of umbilical-cord-derived mesenchymal stem cells
Refs | Cell type | Cell condition | MSCs dose and volume | Route of delivery | Concurrent procedure (if any) |
He et al[18] | WJUC-MSCs | Frozen | 1 × 108/1.5-2.5 mL +/- 1 mL collagen scaffold | IM | CABG for all groups |
Zhao et al[26] | UC-MSCs | N/S | N/S | IC | N/A |
Bartolucci et al[28] | WJUC-MSCs | Frozen | 1 × 106/kg in 100 mL | IV | N/A |
Ulus et al[25] | UC-MSCs | Frozen | 23 × 106 | IM | CABG for all groups |
Gao et al[21] | WJUC- MSCs | Fresh | 6 × 106 | IC | N/A |
- Citation: Safwan M, Bourgleh MS, Aldoush M, Haider KH. Tissue-source effect on mesenchymal stem cells as living biodrugs for heart failure: Systematic review and meta-analysis. World J Cardiol 2024; 16(8): 469-483
- URL: https://www.wjgnet.com/1949-8462/full/v16/i8/469.htm
- DOI: https://dx.doi.org/10.4330/wjc.v16.i8.469